TriangleNCT02675452 · OUTCOME
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Day 1 cycle 1 to 30 days after the last dose of AMG 176; median treatment duration was 1.2 months
What was measured
An AE was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was an AE that started on or after the first dose of investigational product (AMG 176) up to 30 days after the end of investigational product. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests were reported as TEAEs. A treatment-related AE was any TEAE that per investigator review had a reasonable possibility of being caused by the investigational product (AMG 176).
Analysis population: The FAS included all participants that received at least 1 dose of AMG 176.
Groups in this outcome
Part 1A Cohort 1 (MM): AMG 176 Dose A BIW
Participants with MM received AMG 176 Dose A BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1A Cohort 2 (MM): AMG 176 Dose B BIW
Participants with MM received AMG 176 Dose B IV BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1A Cohort 3 (MM): AMG 176 Dose C BIW
Participants with MM received AMG 176 Dose C BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1A Cohort 4 (MM): AMG 176 Dose D BIW
Participants with MM received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1A Cohort 5 (MM): AMG 176 Dose E BIW
Participants with MM received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1A Cohort 6 (MM): AMG 176 Dose G BIW
Participants with MM received AMG 176 Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1A Cohort 7 (MM): AMG 176 Dose E Then Dose F BIW
Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1A Cohort 8 (MM): AMG 176 Dose E Then Dose G BIW
Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1A Cohort 9 (MM): AMG 176 Dose E Then Dose H BIW
Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1A Cohort 10 (MM): AMG 176 Dose E Then Dose I BIW
Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1B Cohort 1 (MM): AMG 176 Dose E Then Dose F QW
Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1B Cohort 2 (MM): AMG 176 Dose E Then Dose G QW
Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1B Cohort 3 (MM): AMG 176 Dose E Then Dose H QW
Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H QW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 1B Cohort 4 (MM): AMG 176 Dose E Then Dose I QW
Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I QW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 3A Cohort 1 (AML): AMG 176 Dose D BIW
Participants with AML received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 3A Cohort 2 (AML): AMG 176 Dose E BIW
Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 3A Cohort 3 (AML): AMG 176 Dose E Then Dose F BIW
Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 3A Cohort 4 (Japanese Participants With AML): AMG 176 Dose E Then Dose F QW
Japanese participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 3B Cohort 1 (AML): AMG 176 Dose E QW
Participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 3B Cohort 2 (AML): AMG 176 Dose E Then Dose F QW
Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 3B Cohort 3 (AML): AMG 176 Dose E Then Dose G QW
Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 3C Cohort 1 (Japanese Participants With AML): AMG 176 Dose E QW
Japanese participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle.
Part 3D Cohort 1 (AML): AMG 176 Dose D QW + Itraconazole
Participants with AML received AMG 176 Dose D QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 200 mg itraconazole QD for 7 days in week 1.
Part 4 Cohort 1 (AML): AMG 176 Dose D QW + Azacitidine
Participants with AML received AMG 176 Dose D QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\^2 azacitidine SC or IV QD for 7 days in week 1.
Part 4 Cohort 2 (AML): AMG 176 Dose E QW + Azacitidine
Participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\^2 azacitidine SC or IV QD for 7 days in week 1.
Part 4 Cohort 3 (AML): AMG 176 Dose E Then Dose F QW + Azacitidine
Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\^2 azacitidine SC or IV QD for 7 days in week 1.
Part 4 Cohort 4 (AML): AMG 176 Dose E Then Dose G QW + Azacitidine
Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\^2 azacitidine SC or IV QD for 7 days in week 1.
Part 4 Cohort 5A (AML): AMG 176 Dose E BIW + Azacitidine
Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\^2 azacitidine SC or IV QD for 7 days in week 1.
Part 4 Cohort 5B (AML): AMG 176 Dose E the Dose G BIW + Azacitidine
Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\^2 azacitidine SC or IV QD for 7 days in week 1.
| Group | Source count |
|---|---|
| Part 1A Cohort 1 (MM): AMG 176 Dose A BIW | 3 |
| Part 1A Cohort 2 (MM): AMG 176 Dose B BIW | 3 |
| Part 1A Cohort 3 (MM): AMG 176 Dose C BIW | 4 |
| Part 1A Cohort 4 (MM): AMG 176 Dose D BIW | 3 |
| Part 1A Cohort 5 (MM): AMG 176 Dose E BIW | 3 |
| Part 1A Cohort 6 (MM): AMG 176 Dose G BIW | 2 |
| Part 1A Cohort 7 (MM): AMG 176 Dose E Then Dose F BIW | 4 |
| Part 1A Cohort 8 (MM): AMG 176 Dose E Then Dose G BIW | 4 |
| Part 1A Cohort 9 (MM): AMG 176 Dose E Then Dose H BIW | 5 |
| Part 1A Cohort 10 (MM): AMG 176 Dose E Then Dose I BIW | 5 |
| Part 1B Cohort 1 (MM): AMG 176 Dose E Then Dose F QW | 3 |
| Part 1B Cohort 2 (MM): AMG 176 Dose E Then Dose G QW | 3 |
| Part 1B Cohort 3 (MM): AMG 176 Dose E Then Dose H QW | 3 |
| Part 1B Cohort 4 (MM): AMG 176 Dose E Then Dose I QW | 3 |
| Part 3A Cohort 1 (AML): AMG 176 Dose D BIW | 5 |
| Part 3A Cohort 2 (AML): AMG 176 Dose E BIW | 5 |
| Part 3A Cohort 3 (AML): AMG 176 Dose E Then Dose F BIW | 5 |
| Part 3A Cohort 4 (Japanese Participants With AML): AMG 176 Dose E Then Dose F QW | 2 |
| Part 3B Cohort 1 (AML): AMG 176 Dose E QW | 4 |
| Part 3B Cohort 2 (AML): AMG 176 Dose E Then Dose F QW | 3 |
| Part 3B Cohort 3 (AML): AMG 176 Dose E Then Dose G QW | 4 |
| Part 3C Cohort 1 (Japanese Participants With AML): AMG 176 Dose E QW | 4 |
| Part 3D Cohort 1 (AML): AMG 176 Dose D QW + Itraconazole | 10 |
| Part 4 Cohort 1 (AML): AMG 176 Dose D QW + Azacitidine | 5 |
| Part 4 Cohort 2 (AML): AMG 176 Dose E QW + Azacitidine | 4 |
| Part 4 Cohort 3 (AML): AMG 176 Dose E Then Dose F QW + Azacitidine | 4 |
| Part 4 Cohort 4 (AML): AMG 176 Dose E Then Dose G QW + Azacitidine | 13 |
| Part 4 Cohort 5A (AML): AMG 176 Dose E BIW + Azacitidine | 10 |
| Part 4 Cohort 5B (AML): AMG 176 Dose E the Dose G BIW + Azacitidine | 13 |
Reported measurements
TEAEs
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1A Cohort 1 (MM): AMG 176 Dose A BIW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 2 (MM): AMG 176 Dose B BIW | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 3 (MM): AMG 176 Dose C BIW | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 4 (MM): AMG 176 Dose D BIW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 5 (MM): AMG 176 Dose E BIW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 6 (MM): AMG 176 Dose G BIW | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 7 (MM): AMG 176 Dose E Then Dose F BIW | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 8 (MM): AMG 176 Dose E Then Dose G BIW | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 9 (MM): AMG 176 Dose E Then Dose H BIW | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 10 (MM): AMG 176 Dose E Then Dose I BIW | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 1B Cohort 1 (MM): AMG 176 Dose E Then Dose F QW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1B Cohort 2 (MM): AMG 176 Dose E Then Dose G QW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1B Cohort 3 (MM): AMG 176 Dose E Then Dose H QW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1B Cohort 4 (MM): AMG 176 Dose E Then Dose I QW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 3A Cohort 1 (AML): AMG 176 Dose D BIW | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 3A Cohort 2 (AML): AMG 176 Dose E BIW | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 3A Cohort 3 (AML): AMG 176 Dose E Then Dose F BIW | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 3A Cohort 4 (Japanese Participants With AML): AMG 176 Dose E Then Dose F QW | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 3B Cohort 1 (AML): AMG 176 Dose E QW | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 3B Cohort 2 (AML): AMG 176 Dose E Then Dose F QW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 3B Cohort 3 (AML): AMG 176 Dose E Then Dose G QW | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 3C Cohort 1 (Japanese Participants With AML): AMG 176 Dose E QW | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 3D Cohort 1 (AML): AMG 176 Dose D QW + Itraconazole | 10 | Not reported | Not reported | Not reported | Not reported |
| Part 4 Cohort 1 (AML): AMG 176 Dose D QW + Azacitidine | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 4 Cohort 2 (AML): AMG 176 Dose E QW + Azacitidine | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 4 Cohort 3 (AML): AMG 176 Dose E Then Dose F QW + Azacitidine | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 4 Cohort 4 (AML): AMG 176 Dose E Then Dose G QW + Azacitidine | 13 | Not reported | Not reported | Not reported | Not reported |
| Part 4 Cohort 5A (AML): AMG 176 Dose E BIW + Azacitidine | 10 | Not reported | Not reported | Not reported | Not reported |
| Part 4 Cohort 5B (AML): AMG 176 Dose E the Dose G BIW + Azacitidine | 13 | Not reported | Not reported | Not reported | Not reported |
Treatment-related TEAEs
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1A Cohort 1 (MM): AMG 176 Dose A BIW | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 2 (MM): AMG 176 Dose B BIW | 1 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 3 (MM): AMG 176 Dose C BIW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 4 (MM): AMG 176 Dose D BIW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 5 (MM): AMG 176 Dose E BIW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 6 (MM): AMG 176 Dose G BIW | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 7 (MM): AMG 176 Dose E Then Dose F BIW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 8 (MM): AMG 176 Dose E Then Dose G BIW | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 9 (MM): AMG 176 Dose E Then Dose H BIW | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 1A Cohort 10 (MM): AMG 176 Dose E Then Dose I BIW | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 1B Cohort 1 (MM): AMG 176 Dose E Then Dose F QW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1B Cohort 2 (MM): AMG 176 Dose E Then Dose G QW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1B Cohort 3 (MM): AMG 176 Dose E Then Dose H QW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1B Cohort 4 (MM): AMG 176 Dose E Then Dose I QW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 3A Cohort 1 (AML): AMG 176 Dose D BIW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 3A Cohort 2 (AML): AMG 176 Dose E BIW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 3A Cohort 3 (AML): AMG 176 Dose E Then Dose F BIW | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 3A Cohort 4 (Japanese Participants With AML): AMG 176 Dose E Then Dose F QW | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 3B Cohort 1 (AML): AMG 176 Dose E QW | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 3B Cohort 2 (AML): AMG 176 Dose E Then Dose F QW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 3B Cohort 3 (AML): AMG 176 Dose E Then Dose G QW | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 3C Cohort 1 (Japanese Participants With AML): AMG 176 Dose E QW | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 3D Cohort 1 (AML): AMG 176 Dose D QW + Itraconazole | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 4 Cohort 1 (AML): AMG 176 Dose D QW + Azacitidine | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 4 Cohort 2 (AML): AMG 176 Dose E QW + Azacitidine | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 4 Cohort 3 (AML): AMG 176 Dose E Then Dose F QW + Azacitidine | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 4 Cohort 4 (AML): AMG 176 Dose E Then Dose G QW + Azacitidine | 11 | Not reported | Not reported | Not reported | Not reported |
| Part 4 Cohort 5A (AML): AMG 176 Dose E BIW + Azacitidine | 8 | Not reported | Not reported | Not reported | Not reported |
| Part 4 Cohort 5B (AML): AMG 176 Dose E the Dose G BIW + Azacitidine | 8 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 4
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 3
- group Id
- OG005
- value
- 2
- group Id
- OG006
- value
- 4
- group Id
- OG007
- value
- 4
- group Id
- OG008
- value
- 5
- group Id
- OG009
- value
- 5
- group Id
- OG010
- value
- 3
- group Id
- OG011
- value
- 3
- title
- TEAEs
- categories
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 3
- group Id
- OG005
- value
- 2
- group Id
- OG006
- value
- 3
- group Id
- OG007
- value
- 2
- group Id
- OG008
- value
- 5
- group Id
- OG009
- value
- 5
- group Id
- OG010
- value
- 3
- group Id
- OG011
- value
- 3
- title
- Treatment-related TEAEs
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 4
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 3
- group Id
- OG005
- value
- 2
- group Id
- OG006
- value
- 4
- group Id
- OG007
- value
- 4
- group Id
- OG008
- value
- 5
- group Id
- OG009
- value
- 5
- group Id
- OG010
- value
- 3
- group Id
- OG011
- value
- 3
- units
- Participants
- description
- An AE was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was an AE that started on or after the first dose of investigational product (AMG 176) up to 30 days after the end of investigational product. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests were reported as TEAEs. A treatment-related AE was any TEAE that per investigator review had a reasonable possibility of being caused by the investigational product (AMG 176).
- groups
- description
- Participants with MM received AMG 176 Dose A BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
- id
- OG000
- title
- Part 1A Cohort 1 (MM): AMG 176 Dose A BIW
- description
- Participants with MM received AMG 176 Dose B IV BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
- id
- OG001
- title
- Part 1A Cohort 2 (MM): AMG 176 Dose B BIW
- description
- Participants with MM received AMG 176 Dose C BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
- id
- OG002
- title
- Part 1A Cohort 3 (MM): AMG 176 Dose C BIW
- description
- Participants with MM received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
- id
- OG003
- title
- Part 1A Cohort 4 (MM): AMG 176 Dose D BIW
- description
- Participants with MM received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
- id
- OG004
- title
- Part 1A Cohort 5 (MM): AMG 176 Dose E BIW
- description
- Participants with MM received AMG 176 Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
- id
- OG005
- title
- Part 1A Cohort 6 (MM): AMG 176 Dose G BIW
- description
- Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
- id
- OG006
- title
- Part 1A Cohort 7 (MM): AMG 176 Dose E Then Dose F BIW
- description
- Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
- id
- OG007
- title
- Part 1A Cohort 8 (MM): AMG 176 Dose E Then Dose G BIW
- description
- Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
- id
- OG008
- title
- Part 1A Cohort 9 (MM): AMG 176 Dose E Then Dose H BIW
- description
- Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.
- id
- OG009
- title
- Part 1A Cohort 10 (MM): AMG 176 Dose E Then Dose I BIW
- description
- Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.
- id
- OG010
- title
- Part 1B Cohort 1 (MM): AMG 176 Dose E Then Dose F QW
- description
- Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.
- id
- OG011
- title
- Part 1B Cohort 2 (MM): AMG 176 Dose E Then Dose G QW
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- The FAS included all participants that received at least 1 dose of AMG 176.
- reporting Status
- POSTED
- time Frame
- Day 1 cycle 1 to 30 days after the last dose of AMG 176; median treatment duration was 1.2 months
- title
- Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice